IP Library › Granted Patent US 12,491,200
Granted Patent B2
US 12,491,200 · App. 17/613,909 · Granted Dec 9, 2025

Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome

Inventors: Ramachandra Mukunda (Potomac, MD); Jagadeesh Sridhara Rao (Ashburn, VA); Amar R. Mukunda (Bethesda, MD)
Assignee: IGC Pharma IP, LLC
A61K31/658A61K9/0053A61K31/166A61K31/40A61K31/495A61K31/496A61K31/519A61K31/5513A61K47/22A61K47/26A61K47/44A61K47/46A61P25/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,200
App. No.
17/613,909
Granted
Dec 9, 2025
Kind
B2
Abstract

This invention relates to compositions and methods for treating stammering/stuttering and Tourette syndrome (TS) in humans, using a formulation comprising of a combination of a Cannabis compound, or compounds.

Claims (20)

1 . A method for treating a patient suffering from stammering, stuttering, or Tourette syndrome comprising administering to said patient a composition comprising (a) an atypical antipsychotic drug; and (b) tetrahydrocannabinol (THC) in the range of 0.2 μg/kg to 0.035 mg/kg patient weight, or cannabidiol (CBD) in the range of 0.2 μg/kg to 0.035 mg/kg patient weight, or both the THC and the CBD each in the range of 0.2 μg/kg to 0.035 mg/kg patient weight.

2 . A method according to claim 1 wherein said patient is orally administered the THC in a daily dose of up to 2.5 mg.

3 . A method according to claim 1 wherein said patient is orally administered the CBD in a daily dose of up to 2.5 mg.

4 . A method according to claim 1 wherein the atypical antipsychotic drug is clozapine.

5 . A method according to claim 1 wherein the THC is organic.

6 . A method according to claim 1 wherein the THC is synthetic.

7 . A method according to claim 1 wherein the atypical antipsychotic drug is selected from the group consisting of risperidone, clozapine, olanzapine, ziprasidone, tiapride, sulpiride, and aripiprazole in an amount that lowers the incidence of stammering.

8 . A method according to claim 7 wherein said patient is administered the THC in a daily dose of up to 2.5 mg, the CBD in a daily dose of up to 2.5 mg, and the atypical antipsychotic drug is selected from the group consisting of risperidone, tiapride, sulpiride, and aripiprazole.

9 . A method according to claim 8 wherein said composition is orally administered.

10 . A method according to claim 9 wherein said composition is in the form of oral drops or an oral spray.

11 . A method according to claim 8 wherein the THC is organic.

12 . A method according to claim 8 wherein the THC is synthetic.

13 . A method for treating a 70 kg human patient suffering from stammering, stuttering, or Tourette syndrome comprising administering to said patient a composition comprising (a) a dissolved resin extracted from Cannabis or hemp flowers, (b) an atypical antipsychotic drug, and (c) water; the resin containing (i) tetrahydrocannabinols (THC) in the range of 14 μg to 2.5 mg, or (ii) cannabidiols (CBD) in the range of 14 μg to 2.5 mg, or both the THC and the CBD each in the range of about 14 μg to 2.5 mg.

14 . A method according to claim 13 wherein said composition comprises both the THC and the CBD.

15 . A method according to claim 14 wherein the THC and/or the CBD are at least 99% of cannabinoid compounds in the resin.

16 . A method according to claim 15 wherein the THC is organic.

17 . A method according to claim 13 wherein the atypical antipsychotic drug is selected from the group consisting of risperidone, clozapine, olanzapine, ziprasidone, tiapride, sulpiride, and aripiprazole in an amount that lowers the incidence of stammering.

18 . A method according to claim 17 wherein said composition comprises both the THC and the CBD, and the atypical antipsychotic drug is selected from the group consisting of risperidone, tiapride, sulpiride, and aripiprazole.

19 . A method according to claim 13 wherein the atypical antipsychotic drug is clozapine.

20 . A method according to claim 13 wherein said composition is administered in the form of oral drops or an oral spray.

Assignments (4)
CHANGE OF NAME Recorded Aug 26, 2025
From: INDIA GLOBALIZATION CAPITAL, INC.
To: IGC PHARMA, INC.
Reel/Frame 072543/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2025
From: IGC PHARMA, INC.
To: IGC PHARMA IP, LLC
Reel/Frame 072560/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: MUKUNDA, RAMACHANDRA; RAO, JAGADEESH SRIDHARA; MUKUNDA, AMAR R.
To: INDIA GLOBALIZATION CAPITAL, INC.
Reel/Frame 059137/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2021
From: MUKUNDA, RAMACHANDRA; RAO, JAGADEESH SRIDHARA; MUKUNDA, AMAR R.
To: INDIA GLOBALIZATION CAPITAL, INC.
Reel/Frame 058200/0080 →
Continuity (2)
Provisional Application 62852257 · May 23, 2019
Related Publication 20220257560A1 · Aug 18, 2022
References Cited (87)
US 10117891B2 · Mukunda et al. · 2018 [cited by applicant]
US 10596159B2 · Mukunda et al. · 2020 [cited by applicant]
US 10722545B2 · Kariman · 2020 [cited by applicant]
US 10751300B2 · Mukunda et al. · 2020 [cited by applicant]
US 10933082B2 · Mukunda et al. · 2021 [cited by applicant]
US 11065225B1 · Cao · 2021 [cited by applicant]
US 11197845B2 · Brener et al. · 2021 [cited by applicant]
US 20160000815A1 · Bird · 2016 [cited by applicant]
US 20160271141A1 · Chipkin · 2016 [cited by applicant]
US 20170027978A1 · Mukunda et al. · 2017 [cited by applicant]
US 20170348276A1 · Bryson · 2017 [cited by examiner]
US 20180064055A1 · Lewis et al. · 2018 [cited by applicant]
US 20180078523A1 · Shmulewitz et al. · 2018 [cited by applicant]
US 20180161285A1 · Mukunda et al. · 2018 [cited by applicant]
US 20180228788A1 · Mukunda et al. · 2018 [cited by applicant]
US 20190030062A1 · Mukunda et al. · 2019 [cited by applicant]
US 20190201463A1 · Kariman · 2019 [cited by applicant]
US 20200046722A1 · Mukunda · 2020 [cited by applicant]
US 20200179342A1 · Mukunda et al. · 2020 [cited by applicant]
US 20200383935A1 · Mukunda et al. · 2020 [cited by applicant]
US 20210023053A1 · Mukunda et al. · 2021 [cited by applicant]
US 20210353705A1 · Mukunda et al. · 2021 [cited by applicant]
US 20220241244A1 · Mukunda et al. · 2022 [cited by applicant]
US 20220257560A1 · Mukunda et al. · 2022 [cited by applicant]
US 20220265598A1 · Cao · 2022 [cited by applicant]
WO 2016044370A1 · 2016 [cited by applicant]
WO 2016118391A1 · 2016 [cited by applicant]
WO 2016160542A1 · 2016 [cited by applicant]
WO 2017027651A1 · 2017 [cited by applicant]
WO 2017218629A1 · 2017 [cited by applicant]
WO 2018160510A1 · 2018 [cited by applicant]
WO 2019190608A1 · 2019 [cited by applicant]
WO 2020237247A1 · 2020 [cited by applicant]
WO 2022016160A1 · 2022 [cited by applicant]
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs. May 2019;33(5):417-430. PMID: 30977108. (Year: 2019). [cited by examiner]
Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. Int J Mol Sci. Aug. 10, 2017;18(8):1739. PMID: 28796166. (Year:… [cited by examiner]
Budman, “The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview,” Drugs 2014;74(11):1177-93. PMID: 25034359. (Year: 2014). [cited by examiner]
Howell; International Preliminary Report On Patentability issued in PCT/US2020/034602; mailed Apr. 27, 2022; four pages. [cited by applicant]
Tanigawa; PCT Art. 34 Amendment in PCT/US2020/034602 and Letter Indicating Differences Between Original Claims And New Pending Claims; dated Mar. 15, 2021; five pages. [cited by applicant]
Anis et al. “Medical cannabis for Gilles de la Tourette syndrome: An open-label prospective study” Behav Neurol; Mar. 2022; 2022: 5141773. doi: 10.1155/2022/5141773, 10 pages. [cited by applicant]
Baratta et al. “Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation” Front Pharmacol; May 2022; 13: 888903, doi: 10.3389/fphar.2022.888903, 17 pages. [cited by applicant]
Bilbao & Spanagel “Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications” BMC Med; Aug. 2022; 20(1): 259, doi: 10.1186/s12916-022-02459-1, 29 pages. [cited by applicant]
Evans et al. “A comparison of Sativex® and Aseco® for treatment of severe motor and vocal tics; a single case report” Ann Forensic Res Anal; Nov. 2016; 3(2): 1032, three pages. [cited by applicant]
Ganos et al. “Clinical practice patterns in tic disorders among Movement Disorder Society members” Tremor Other Hyperkinet Mov; Oct. 2021; 11: 43, doi: 10.5334/tohm.656, 12 pages. [cited by applicant]
Grotenhermen & Müller-Vahl “The therapeutic potential of cannabis and cannabinoids” Dtsch Arztebl Int; Jul. 2012; 109(29-30): 495-501. [cited by applicant]
Grotenhermen & Müller-Vahl “Two decades of the International Association for Cannabinoid Medicines: 20 Years of supporting research and activities toward the medicinal use of cannabis and cannabinoids” Cannabis Cannabin… [cited by applicant]
Jakubovski & Müller-Vahl “Speechlessness in Gilles de la Tourette syndrome: Cannabis-based medicines Improve severe vocal blocking tics in two patients” Int J Mol Sci; Aug. 2017; 18: 1739, doi: 10.3390/ijms18081739, six… [cited by applicant]
Jakubovski et al. “The CANNA-TICS study protocol: A randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorder… [cited by applicant]
Kluger et al. “The therapeutic potential of cannabinoids for movement disorders” Mov Disord; Mar. 2015 ePub Feb. 2015; 30(3): 313-327. [cited by applicant]
Lacroix et al. “What do we know about medical cannabis in neurological disorders and what are the next steps?” Front Pharmacol; Apr. 2022; 13: 883987, doi: 10.3389/fphar.2022.883987, ten pages. [cited by applicant]
Legare et al. “Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals” Pharmacology; Mar. 2022 ePub Jan. 2022; 107(3-4): 131-149. [cited by applicant]
Lim et al. “A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders” Clin Psychopharmacol Neurosci; Nov. 2017; 15(4): 301-312. [cited by applicant]
Müller-Vahl et al. “Combined treatment of Tourette syndrome with Δ9-THC and dopamine receptor antagonists” J Cannabis Therap; Jun. 2002; 2(3-4): 143-152. [cited by applicant]
Namdar et al. “Chronological review and rational and future prospects of cannabis-based drug development” Molecules; Oct. 2020; 25(20): 4821, doi: 10.3390/molecules25204821, 13 pages. [cited by applicant]
Schwittay et al. “Tic reduction in adult onset Gilles de la Tourette syndrome using as required nabiximols spray” Tremor Other Hyperkinet Mov; Aug. 2021; 11(1): 33, doi: 10.5334/tohm.613, five pages. [cited by applicant]
Szejko et al. “Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome: Case report” Eur J Med Case Rep; May 2018; 2(2): 39-41. [cited by applicant]
Szejko et al. “Vaporized cannabis is effective and well-tolerated in an adolescent with Tourette syndrome” Med Cannabis Cannabinoids; Jan. 2019; 2(1): 60-63. [cited by applicant]
Szejko et al. “Cannabis improves obsessive-compulsive disorder—Case report and review of the literature” Front Psychiatry; Jul. 2020; 11: 681, doi: 10.3389/fpsyt.2020.00681, eight pages. [cited by applicant]
Szejko et al. “Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome” Neurol Neurochir Pol; 2022 ePub Oct. 2021; 56(1): 28-38. [cited by applicant]
Szejko & Müller-Vahl “Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome” in the Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics—Part B (Lavoie & Cavanna… [cited by applicant]
Thaler et al. “Single center experience with medical cannabis in Gilles de la Tourette syndrome” Parkinsonism Relat Disord; Apr. 2019 ePub Oct. 2018; 61: 211-213. [cited by applicant]
Trainor et al. “Severe motor and vocal tics controlled with Sativex®” Australas Psychiatry; Aug. 2016; 24(6): 541-544. [cited by applicant]
Whiting et al. “Cannabinoids for medical use A systematic review and meta-analysis” JAMA; Jun. 2015; 313(24): 2456-2473. [cited by applicant]
Wong & Wilens “Medical cannabinoids in children and adolescents: A systematic review” Pediatrics; Nov. 2017; 140(5): e20171818, doi: 10.1542/peds.2017-1818, 16 pages. [cited by applicant]
International Search Report & Written Opinion issued in PCT/US2020/034602; mailed Aug. 27, 2020. [cited by applicant]
Abi-Jaoude et al. “Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome” J Neuropsychiatry Clin Neurosci; Fall 2017; 29(4): 391-400. [cited by applicant]
Curtis et al. “Cannabinoids for Tourette's syndrome” Cochrane Database Syst Rev; Oct. 2009; 2009(4): CD006565, 12 pages. [cited by applicant]
Kanaan et al. “Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols” Brain Sci; Apr. 2017; 7: 47, six pages. [cited by applicant]
Khan et al. “The therapeutic role of cannabidiol in mental health: A systematic review” J Cannabis Res; Jan. 2020; 2 (1): 2, 21 pages. [cited by applicant]
Koppel “Cannabis in the treatment of dystonia, dyskenias, and tics” Neurotherapeutics; Oct. 2015; 12(4): 788-792. [cited by applicant]
Milosev et al. “Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: Results from a retrospective analysis and online survey” Cannabis Cannabinoid Res; Dec. 2019; 4(4): 265-274. [cited by applicant]
Müller-Vahl et al. “Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome” Acta Psychiatr Scand; Dec. 1998; 98(6): 502-506. [cited by applicant]
Müller-Vahl et al. “Influence of treatment of Tourette syndrome with A9-tetrahydrocannabinol (A9-THC) on neuropsychological performance” Pharmacopsychiatry; Jan. 2001; 34(1): 19-24. [cited by applicant]
Müller-Vahl et al. “Treatment of Tourette-syndrome with Δ9-tetrahydrocannabinol (THC): A randomized crossover trial” Pharmacopsychiatry; Mar. 2002; 35(2): 57-61. [cited by applicant]
Müller-Vahl et al. “Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (Δ9-THC): No influence on neuropsychological performance” Neuropsychopharmacology; Feb. 2003; 28(2): 384-388. [cited by applicant]
Müller-Vahl “Cannabinoids reduce symptoms of Tourette's syndrome” Expert Opin Pharmacother; Oct. 2003; 4 (10): 1717-1725. [cited by applicant]
Müller-Vahl “Treatment of Tourette syndrome with cannabinoids” Behav Neurol; 2013; 27(1): 119-124. [cited by applicant]
Müller-Vahl et al. “Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome” Neuropsycho-pharmacolgy; Jul. 2020; 45(8): 1323-1329. [cited by applicant]
Müller-Vahl et al. “Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome” Neuropsycho-pharmacology; Feb. 2003; 28(2): 384-388. [cited by applicant]
Seidman & Seidman “A review of the current treatment of Tourette syndrome” J Pediatr Pharmacol Ther; Jun. 2020; 25(5): 401-412. [cited by applicant]
Szejko et al. “Possible role of the endocannabinoid system in Tourette syndrome” Recent Advances in Cannabinoid Research (Costain & Laprairie, eds.); Nov. 2018; doi: 10.5772/intechopen.79895, 119-135. [cited by applicant]
The extended European search report issued by the European Patent Office on Jun. 12, 2023, which corresponds to European Patent Application No. 20809522.4-1112 and is related to U.S. Appl. No. 17/613,909. [cited by applicant]
Pichler et al., “Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report”, The International Journal of Psychiatry in Medicine, 54(2):150-156, Jul. … [cited by applicant]
Brzozowska et al., “The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions” Neuropsychopharmacology; Oct. 2017; 42(11): 2222-2231. [cited by applicant]
Di Forti et al., “Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study” Lancet Psychology; Mar. 2015 Epub Feb. 2015; 2(3): 233-238, doi: … [cited by applicant]
Serag et al., “Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: A systematic review and meta-analysis” European Journal of Clinical Pharmacology; Oct. 2024; 80(10): 1483-1493. [cited by applicant]
Xiong et al., “Prevalence of Tourette syndrome among children and adolescents in the United States, 2016-2022” BMC Public Health; Oct. 2024; 24(1): 2699, doi: 10.1186/s12889-024-20216-2. [cited by applicant]